TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Analgesia in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 55-80 years old patients who come to orthopaedic polyclinic~* underwent TKA procedure~* have osteoarthritis~* consumed pain killer and anti inflamatory drugs routinely~Exclusion Criteria:~* psychiatric disorder~* have history of renal disease~* histroy of chronic neurophatic~* have genu arthritis that caused by rheumatid arthritis and infection~* diabetic and obesity~* coagulopathy~* patients with severe pain that needed immediate analgesia regimen

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): celecoxib 400mg and pregabaline 150mg 1 hour before operation
- Group 2 (Type: ACTIVE_COMPARATOR): celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
- Group 3 (Type: PLACEBO_COMPARATOR): No treatment given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males~* Age: 50 to 65 inclusive~* Body mass index of 25 to 30 kg / m² (inclusive~Exclusion Criteria:~* Hypertriglyceridemia or known hypercholesterolemia, treated or not~* Serology HIV and / or HCV positive

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Collaborative Perinatal Mental Health and Parenting Support in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mothers with infants 6 weeks - 3 months old~* English or Spanish speaking~* Access to a telephone~* Currently or at some point during pregnancy received treatment for a mental health condition (counseling and/or medications) at a participating community health center in the Seattle, Washington area~Exclusion Criteria:~* Currently experiencing an acute crisis (e.g., severe domestic violence, homelessness, hospitalization, imprisonment)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Promoting First Relationships® (PFR) (Type: EXPERIMENTAL): 10 week home visiting program
- Parent Information Packet (Type: NO_INTERVENTION): A packet is mailed to the families, including handouts related to child development, health, and local resources.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus for at least 12 months~* HbA1c: 7.5-10.0%~* An antidiabetic regimen that has been stable for at least 3 months~* Able and willing to perform SMBG testing as per protocol~Exclusion Criteria:~* Use of any insulin preparations other than NPH or glargine within the past 6 months~* Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or judged to be using inadequate contraceptive measures (adequate contraceptive measures includes: sterilization, intrauterine devices, oral contraceptives, or consistent use of barrier methods)~* Known or suspected allergy to trial product or agents related to trial product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPTIONS Spinal Cord Stimulation Programming Parameters

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidate for Spinal Cord Stimulation (SCS) system (trial and implant) per labeled indication(back and leg pain)~* Willing and able to provide a signed and dated informed consent~* At least 18 years old at the time of informed consent~* Willing and able to attend visits and comply with the study protocol~* Capable of using the patient programmer and recharging the neurostimulator~* Willing to not increase pain medications from baseline through the 3-Month Visit~Exclusion Criteria:~* Currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound study results.~* Psychological or other health conditions that would interfere with the subject's ability to fulfill the requirements of the protocol.~* Trialed or implanted with SCS, subcutaneous stimulation, peripheral nerve stimulation or an implantable intrathecal drug delivery system~* Implanted with a cardiac device (e.g., pacemaker, defibrillator)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label treatment (Type: OTHER): Spinal Cord Stimulation (SCS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 with chronic genotype 2 or 3 HCV infection~* HCV RNA \> 10,000 IU/mL at screening~* Subjects must be treatment naive or treatment experienced~* Presence or absence of cirrhosis; a liver biopsy may be required~* Healthy according to medical history and physical examination with the exception of HCV diagnosis~* Agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication~Exclusion Criteria:~* Prior use of any other inhibitor of the HCV NS5B Polymerase~* History of any other clinically significant chronic liver disease~* Evidence of or history of decompensated liver disease~* HIV or chronic hepatitis B virus (HBV) infection~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of immunosuppressive agents or immunomodulatory agents~* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study or not be in the best interest of the subject in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo 12 Weeks (GT2/3) (Type: PLACEBO_COMPARATOR): Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
- SOF 12 Weeks (GT2/3) (Type: EXPERIMENTAL): Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
- SOF 24 Weeks (GT3) (Type: EXPERIMENTAL): SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criterion:~* Patients scheduled for elective or urgent CABG of two to six vessels~Exclusion Criteria:~Preoperative:~* Hemoglobin of less than 110g/L~* Under 18 years of age~* Body mass less than 75kg~* Presence of an intra-aortic balloon pump~* Emergency surgery, requiring operative intervention within 24 hours of consultation to the cardiac surgery team~* Need for cardiac surgical intervention in addition to planned CABG (with the exception of patent foramen ovale closure)~* Ejection fraction (EF) of less than 50%, as determined by echocardiogram or angiography~* Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg (as estimated by right ventricular systolic pressure (RVSP))~* Presence of infectious endocarditis~* Hepatic failure with impaired liver function, including International Normalized Ratio (INR) greater than 1.5~* Known diagnosed bleeding disorder~* History of heparin induced thrombocytopenia and thrombosis (HITT)~* Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with urine output less than 10ml/hour~* Allergy to tranexamic acid~* Pregnancy~Intraoperative:~* Discovery of infectious endocarditis~* Need for cardiac surgical intervention in addition to planned coronary CABG~* Development of allergic reaction to tranexamic acid following intravenous infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Trial Drug (Type: EXPERIMENTAL): Solution containing 2 grams tranexamic acid + normal saline
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically or histologically diagnosed with multiple myeloma stage II/III~* Participants without preceding cytostatic (tending to retard cellular activity and multiplication) treatment (pretreatment with radiation or dexamethasone is allowed)~* Agree to use one of the contraception methods as defined in the protocol~* Karnofsky performance status 60 percent or more~* Adequate laboratory test values~Exclusion Criteria:~* Non-secretory multiple myeloma~* Estimated life expectancy less than 3 months~* History of cancer (except basal cell carcinoma) in the last 5 years~* Peripheral neuropathy (disorder of the peripheral nerves) grade 2 or more~* Positive human immunodeficiency virus test and active hepatitis B and/or hepatitis C~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FEV1 \> 70 % of predicted normal pre-bronchodilator~* Documented history of asthma~* Presence of allergic sensitivity~Exclusion Criteria:~* Clinically relevant disease and/or abnormality (past or present), which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study.~* Symptomatic allergic rhinitis~* Any clinical relevant abnormal findings in physical examination or assessment which may put the patient at risk because of participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD8848 (30 μg PILOT part and 60 μg MAIN part)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* known or suspected squamous cell neoplasia~* 18 years or older

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): imaging with proflavine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oscillatory Contributions to Working Memory and Attention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of # 18 \<36. - Right-handed.~* Be in good health determined by the investigator on basis of medical history, physical and neurological exam; for EEG-only sessions no physical or neurological exams will be performed;~* Female subjects must be two years past menopause, surgically sterile or practicing a medically acceptable method of birth control (does not apply to EEG-only sessions);~* Female subjects must not be pregnant.~* Able to understand and speak English.~* Able to provide written consent prior to admission~Exclusion Criteria:~* History of epilepsy, stroke, brain surgery, cranial metal implants, structural brain lesion, devices that may be affected by TMS or tCS(pacemaker, medication pump, cochlear implant, implanted brain stimulator); - Women who are breast-feeding (self report)\*;~* History of head trauma with loss of consciousness for greater than 5 minutes;~* Any history of seizures;~* Any family history of seizures\*;~* Diabetes requiring insulin treatment\*;~* A serious heart disorder or subjects who have had a heart attack within the last 3 months;~* Subjects who meet DSM-IV criteria for alcohol /drug abuse problems within the last six months;~* Any current Axis I or II diagnoses or past Axis I diagnoses;~* Required use of medication that affects CNS function;~* A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MR machine can cause a displacement or malfunctioning of these devices\*;~* The female subject who is pregnant or planning to become pregnant; or a female subject of child-bearing potential who is not practicing a medically acceptable form of birth control\*;~* The subject has had a diagnosis of cancer in the past 3 years and/or has active neoplastic disease;~* The investigator anticipates that the subject will be unable to comply with the protocol.~* Prohibited Concomitant Treatment: Any investigational medication; antipsychotic, antidepressant; or ECT; Other psychotropic medications including sedative hypnotics (excluding chloral hydrate zaleplon); sumatriptan (and similar agents); anxiolytics and herbals (e.g., St. John's Wort, Kava Kava); an introduction or change in intensity of psychotherapy; any nonpsychopharmacologic drug with psychotropic effects (e.g., antihistamines, beta blockers).~* Colorblindness~* Poor or Uncorrected Vision~* History of fainting/syncope

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 2016-0500-Healthy YoungAdults (Type: EXPERIMENTAL): working memory and attention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.~* Failure of previous treatment with one prior platinum-based chemotherapy regimen.~* Good performance status.~* Adequate bone marrow reserve, renal and hepatic functions.~Exclusion Criteria:~* Serious concomitant systemic disease.~* Inability to take oral medication.~* Inability or unwillingness to take vitamin supplementation and corticosteroids.~* Pregnancy / Breast-feeding.~* Treatment with certain medicines that prevent blood from clotting.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Nonsquamous) (Type: EXPERIMENTAL): Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
- Pemetrexed + Erlotinib (Nonsquamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
- Pemetrexed (Squamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
- Pemetrexed + Erlotinib (Squamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent residence in the study area with no intention of leaving during the surveillance period.~* Obtention of informed consent.~Exclusion Criteria:~* Temporary residence in the study area.~* Absence of informed consent.~* Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.~* A history of a previous, significant adverse reaction to either of the study drugs.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Amodiaquine+pyrimethamine versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 30 to 79 years old~* Triglyceride level 6.8 mmol/L at screening~* LDL-C of 5.7 mmol/L at screening~Exclusion Criteria:~* Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception. The latter are defined as: abstinence, surgical sterilization, oral contraceptives for at least 3 cycles, intrauterine device, implant, depot injection, or barrier method in conjunction with contraceptive foam or jelly.~* Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin~* Subjects receiving statin doses higher than the following: 10-40mg for simvastatin , 20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin. Subjects already treated with atorvastatin at the time of screening are not eligible unless atorvastatin has been discontinued at least 2 months prior to screening~* Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete